Immuneering
Update in progressIMRX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Immuneering Corporation is a late-stage oncology company focused on medicines for broad cancer patient populations in the United States. It is developing IMM-1-104 (atebimetinib), a dual-MEK inhibitor in Phase 3 for cancers including pancreatic and non-small cell lung cancer with RAS or RAF mutations; and IMM-6-415 (envometinib) in Phase 1/2a for solid tumors, plus other deep cyclic inhibitor programs. Partnerships include Regeneron (atebimetinib with Libtayo for RAS-mutant NSCLC) and Eli Lilly (with olomorasib for KRAS G12C NSCLC). Incorporated 2008, headquartered in Cambridge, Massachusetts.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.33
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.28
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section